These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28085177)

  • 1. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
    De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
    Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
    Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
    Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
    Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
    Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.
    Nunez Bragayrac L; Hoffmeyer J; Abbotoy D; Attwood K; Kauffman E; Spiess P; Wagner A; Schwaab T
    World J Urol; 2016 Dec; 34(12):1651-1656. PubMed ID: 27084776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
    Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
    Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
    Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
    Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
    Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
    Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
    Hsiang WR; Kenney PA; Leapman MS
    Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.
    Bölükbas S; Kudelin N; Eberlein M; Fisseler-Eckhoff A; Schirren J
    Thorac Cardiovasc Surg; 2012 Sep; 60(6):390-7. PubMed ID: 22207364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of Surgical Options in Kidney Cancer and Surgical Complications.
    Wasserman M; Sobel D; Pareek G
    Semin Nephrol; 2020 Jan; 40(1):42-48. PubMed ID: 32130965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy.
    Carvalho FLF; Zheng C; Witmer K; O'neill J; Lynch JH; Kowalczyk KJ
    Sci Rep; 2019 Oct; 9(1):15272. PubMed ID: 31649310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
    De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
    Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.